TNF inhibitors

TNF inhibitors

Drug monograph · NCLEX study reference
Trade names	Humira, Enbrel, Remicade
Therapeutic class	Biologic disease-modifying antirheumatic drug
Pharmacologic class	Tumor necrosis factor (TNF) inhibitors
Onset / peak / duration	Effect over weeks; SubQ (most) or IV (infliximab).
Half-life / level	Long; dosed every 1 to 8 weeks by agent.
Routes	IV, SubQ
High-alert (ISMP)	No
Black box warning	Yes (see Safety)
Antidote / reversal	Supportive care.
Pregnancy / lactation	Use case by case under specialist guidance.

Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.

TNF inhibitors (brand names Humira, Enbrel, Remicade) — Biologic disease-modifying antirheumatic drug; Tumor necrosis factor (TNF) inhibitors.

Identification

• Therapeutic class: Biologic disease-modifying antirheumatic drug.
• Pharmacologic class: Tumor necrosis factor (TNF) inhibitors.

Pharmacology

• Mechanism of action: Neutralize TNF-alpha to reduce inflammation in autoimmune disease.
• Onset / peak / duration: Effect over weeks; SubQ (most) or IV (infliximab).
• Half-life / therapeutic level: Long; dosed every 1 to 8 weeks by agent.

Clinical use

• Indications: Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, inflammatory bowel disease.
• Usual dose, route, frequency: SubQ every 1 to 4 weeks (adalimumab, etanercept, golimumab, certolizumab); infliximab IV infusion.
• Maximum dose / adjustments: Hold during serious infection; screen for tuberculosis and hepatitis B before starting.

Safety

• Contraindications: Active serious infection, untreated latent tuberculosis, moderate to severe heart failure (caution).
• Black box warning: Increased risk of serious infections (including tuberculosis reactivation, invasive fungal, and other opportunistic infections) and malignancy (including lymphoma, especially in children and adolescents).
• Interactions: Other immunosuppressants and biologics (infection), live vaccines (avoid).
• Pregnancy / lactation: Use case by case under specialist guidance.
• High-alert: No.

Adverse effects

• Common side effects: Injection-site or infusion reactions, headache, upper respiratory infections.
• Serious effects to report: Serious infection (fever, persistent cough), reactivated tuberculosis or hepatitis B, new lymphoma symptoms, heart failure worsening, demyelinating symptoms.
• Antidote / reversal: Supportive care.

Nursing process

• Assessment before administration: Tuberculosis screening, hepatitis B status, infection signs, vaccination status.
• Interventions during therapy: Screen for and treat latent tuberculosis before starting; hold for active infection; avoid live vaccines; teach SubQ self-injection and site rotation.
• Monitor: Signs of infection, tuberculosis, malignancy surveillance, injection reactions.
• Evaluation / expected outcome: Reduced disease activity.

Patient teaching

• Patient teaching: Report any infection promptly; complete tuberculosis screening; avoid live vaccines; rotate injection sites; store refrigerated.
• Notify provider if: Fever, persistent cough, night sweats, new lumps, signs of infection.
• Administration tips: SubQ self-injection with rotation; refrigerate; let it warm before injecting.